Interestingly, a trend of lower expression of PD-L1 (23.35 ± 10.84 vs. 31.95 ± 3.692, P = 0.11) and PD-L2 (3.523 ± 0.479 vs. 7.847 ± 2.286, P = 0.08) were seen in those BM samples from MDS patients from the high-risk group. The gene discussed is PDCD1LG2; the disease is myelodysplastic syndrome.